Osteo-Pharma

What Osteo-Pharma does

Osteo-Pharma BV is a privately held, development-stage Dutch life sciences company founded in June 2014 and headquartered at Pivot Park in Oss, the Netherlands. The company develops novel medical devices and pharmaceuticals for the local treatment of bone fractures and defects, with primary use cases in orthopedic and dental applications. Its proprietary OsteoActivator™ platform encapsulates EMA- and FDA-approved low molecular weight bone-healing compounds (testosterone and alendronate) in a biodegradable PLGA carrier to achieve sustained local release over a 4–6 week period, simultaneously enhancing osteoblast activity and inhibiting osteoclast activity to produce net new bone growth. The platform is deployed across three formulations: OsteoActivator-P/F (collagen barrier membranes for guided bone regeneration, currently in a Dutch clinical trial for alveolar ridge preservation), OsteoActivator-M (injectable PLGA microspheres for bone defects), and OsteoActivator-C (coatings for orthopedic/dental implants to improve osseointegration).

The company operates a platform-extension model with three named product lines plus a joint venture called Bone-Tech (formed with Emultech in November 2021) targeting disease-modifying treatment of knee osteoarthritis via intraosseous injection of extended-release microspheres under a planned 505(b)(2) regulatory pathway. Revenue is currently zero; the business model is explicitly enterprise-partnership-driven, with Osteo-Pharma seeking co-development and global marketing alliances with pharmaceutical and medical device companies for European and US commercialization rather than building direct sales infrastructure. The company is privately financed by three shareholders (Leader Biomedical BV, Proteales BV, and Gossen Medical BV) and received a €2,098,239 repayable innovation credit from the Dutch Government's RVO agency in June 2016. Its composition-of-matter patent has received EPO notification of intention to grant with parallel filings in the US, China, and Japan, and its lead product OsteoActivator-P received MREC approval in May 2021 and treated its first patient in November 2021.

Name

Osteo-Pharma

Legal name

Osteo-Pharma BV

Website

https://osteo-pharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Osteo-Pharma is a pre-commercial Dutch life sciences company developing OsteoActivator™ PLGA-based sustained-release therapeutics (testosterone and alendronate) for orthopedic, dental, and osteoarthritis applications, targeting enterprise pharma and medical-device co-development partnerships.

Ownership category

akta.pro rank

Product category

Orthopedic and Dental Bone Healing Therapeutics

NAICS

Dental Equipment and Supplies Manufacturing (339114), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Dental Implant Surgery & Bone Grafting (HLABAEAB), Dental Implant Placement (Surgical Implantology) (HLABACAE), Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

Keywords

• Bone healing therapeutics
• Osteoporosis treatment
• Guided bone regeneration
• Biodegradable drug delivery
• Orthopedic medical devices

Headquarters

HQ city

Oss

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Medical Devices and Pharmaceuticals: Osteo-Pharma is a development-stage company focused on developing novel medical devices and pharmaceuticals for orthopedic and dental applications. The company is in preclinical/clinical development stage with products not yet commercially available. Revenue model will involve product sales through strategic partnerships upon successful development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Osteo-Pharma develops novel medical devices and pharmaceuticals for local treatment of bone fractures and defects in orthopedic and dental applications. Its proprietary OsteoActivator™ platform encapsulates low molecular weight bone healing compounds (testosterone and alendronate) in a biodegradable PLGA carrier for sustained local release over 4-6 weeks, simultaneously enhancing osteoblast activity and inhibiting osteoclast activity to achieve net new bone formation.

Product overview

Osteo-Pharma operates as a product-platform company with the proprietary OsteoActivator™ technology platform at its core. The platform enables sustained and controlled release of bone-healing compounds (testosterone and alendronate) via biodegradable carriers (PLGA). The company applies this platform through three distinct product formulations: (1) OsteoActivator-P/F collagen barrier membranes for guided bone regeneration in dental and orthopedic applications; (2) OsteoActivator-M injectable microspheres for local bone defect treatment; and (3) OsteoActivator-C coatings for orthopedic and dental implants to enhance osseointegration. The lead product OsteoActivator-P has received MREC approval and entered clinical trials. A joint venture (Bone-Tech) with Emultech extends the platform to osteoarthritis treatment via intraosseous injection of extended-release microspheres.

Differentiator

Problem solved

Functional benefit

Brands

• OsteoActivator: Proprietary technology platform for sustained release of bone healing compounds (testosterone and alendronate) in biodegradable carriers for enhanced bone formation and inhibited bone resorption.
• Bone-Tech

Products and services

• OsteoActivator-P / OsteoActivator-F Biodegradable collagen barrier membrane coated with OsteoActivator technology to improve guided bone regeneration (GBR) for dental applications and fracture healing. Preclinical data showed 24% increase in new bone within 6 weeks versus uncoated membranes.
• OsteoActivator-M Injectable biodegradable PLGA microspheres releasing testosterone in combination with alendronate for direct placement in bone defects. Demonstrated enhanced bone formation in subchondral compartment up to 0.5mm from defect perimeter.
• OsteoActivator-C Orthopedic implant coating with OsteoActivator technology to enhance osseointegration and prevent implant loosening. Preclinical studies showed increased bone-implant contact (BIC) and trabecular bone formation up to 1.3mm from screw.
• Bone-Tech (Joint Venture) Disease-modifying treatment for osteoarthritis of the knee combining OsteoActivator microspheres with Emultech's microfluidics technology for extended-release of combination therapeutic agents via intraosseous injection. Planned 505(b)(2) regulatory pathway.

Quantifiable outcome

• 24% increase in new bone formation within 6 weeks compared to uncoated collagen membranes in preclinical mini-pig study
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• EmultechcoreStrategic or Co-development Partner · 17 November 2021Joint venture 'Bone-Tech' announced November 17, 2021 to develop first disease-modifying treatment for osteoarthritis of the knee. Combines Osteo-Pharma's OsteoActivator combination drug therapy with Emultech's world-leading microfluidics microsphere technology. Targets subchondral bone remodelling through intraosseous injection. Plans to pursue 505(b)(2) regulatory pathway.
• Radboud University Medical CenterminorStrategic or Co-development PartnerCollaboration with Prof. John Jansen's group at Radboud university medical center (Nijmegen, The Netherlands) for preclinical dental defect study in mini-pigs that demonstrated enhanced bone formation by OsteoActivator-coated collagen membranes.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Orthofix Medical: Orthopedic company with bone growth stimulation and biologics portfolios; directly relevant to Osteo-Pharma's fracture healing and bone defect treatment indications.
• Bioventus: Pure-play orthobiologics company focused on bone healing (e.g., EXOGEN ultrasound bone healing) and osteoarthritis pain management; closest publicly traded comparable to Osteo-Pharma's bone healing and OA programs.
• Curasan: Smaller German dental/orthopedic bone regeneration specialist; comparable European peer with overlapping product categories in dental bone grafting and orthobiologics.
• Geistlich Pharma: Swiss dental regeneration specialist whose Bio-Oss and Bio-Gide products are standards of care in guided bone regeneration; directly comparable to Osteo-Pharma's OsteoActivator-P dental membrane franchise.
• botiss biomaterials: European dental bone and soft tissue regeneration specialist with collagen membranes and bone graft substitutes; a more focused, regional direct peer to Osteo-Pharma's dental GBR product line.

Broad incumbents

• Stryker: Major orthopedic and trauma device company with a portfolio of bone graft and biologics products; directly comparable to Osteo-Pharma's orthopedic fracture healing and implant coating applications.
• Integra LifeSciences: Diversified surgical and orthopedic reconstruction company with regenerative technology (dural repair, dermal, bone) and a meaningful neurosurgery/orthopedic presence; broader incumbent overlapping Osteo-Pharma's bone healing and implant coating indications.
• Medtronic: Global medtech incumbent with Infuse (rhBMP-2), the most established bone graft substitute/orthobiologic; competes directly with Osteo-Pharma's OsteoActivator in orthopedic and dental bone healing indications and would be a natural strategic acquirer or partner.
• DePuy Synthes (Johnson & Johnson MedTech): Largest orthopedic trauma and reconstruction franchise with bone graft substitute offerings and an extensive sales force; directly relevant to Osteo-Pharma's trauma fixation, implant coating, and bone defect indications.

Emerging players

• Emultech: Dutch microfluidics-based microsphere specialist and Osteo-Pharma's joint venture partner in Bone-Tech; relevant as a closely coupled technology partner and comparable in scale and stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/osteo-pharma-bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osteo-Pharma